![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Israel's Teva to Gain From Elan Tysabri Withdrawal
Israel's Teva to Gain From Elan Tysabri Withdrawal
As its stock market performance in recent days suggests, Israeli drugmaker Teva could become a major beneficiary of the withdrawal of Irish drugmaker Elan's novel Tysabri (natalizumab) treatment for multiple sclerosis. Teva markets Copaxone, a rival ethical treatment for the disease, which earned the Israeli company US$261mn in the fourth quarter of 2004.
Tysabri, produced in association with US biotech firm Biogen Idec, had been expected to become a blockbuster product, but the drug has been voluntarily withdrawn following the death of one patient and the reporting of a further case involving a serious central nervous system disease. Elan had also hoped to secure further indications for Crohn's disease and rheumatoid arthritis. Nevertheless, Teva's two rivals hope to shortly resume marketing the drug.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct